Flucytosine: Clinical Trials

34 trials of Flucytosine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 7 terminated, 4 unknown, 3 withdrawn. 17 Phase 1, 14 Phase 2, 6 Not applicable, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 117Completed 7, Terminated 4, Withdrawn 3, Recruiting 1, Suspended 1, Unknown 1
Phase 214Terminated 5, Completed 4, Recruiting 2, Unknown 2, Suspended 1
Not applicable6Completed 5, Unknown 1
Phase 34Unknown 2, Not yet recruiting 1, Terminated 1

Follow Flucytosine: new trials by email Literature Review of Flucytosine trials Research Report on Flucytosine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill - Talaromycosis
Phase 3Not yet recruitingDuke University4282026-11-012026-09-21
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
DB107-RRV, DB107-FC, Radiation Therapy (RT) - High Grade Glioma, MGMT-Unmethylated Glioblastoma
Phase 1 / Phase 2RecruitingUniversity of California, San Francisco702025-01-082026-03-11
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
DB107-RRV, DB107-FC - High Grade Glioma, Anaplastic Astrocytoma
Phase 2RecruitingAshish Shah332024-05-012026-05-28
Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis
AMBITION trial control, Flucytosine - Cryptococcal Meningitis
Phase 2CompletedUniversity of Minnesota482024-04-092025-08-27
Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis
Amphotericin B Colloidal Dispersion, flucytosine, fluconazole - Cryptococcal Meningitis
Not applicableUnknownPeking Union Medical College Hospital302022-08-222022-07-22
A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract
TMV-018 + 5-FC, TMV-018 + anti-PD-1, TMV-018 + 5-FC + anti-PD-1 - Gastrointestinal Cancer
Phase 1WithdrawnThemis Bioscience GmbH2020-11-232020-11-25
Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis
Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week - Cryptococcal Meningitis
CompletedUniversity of Pharmacy, Yangon302020-10-012022-04-21
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
TG6002, Flucytosine (5-FC) - Colorectal Neoplasms
Phase 1 / Phase 2TerminatedTransgene152020-01-172023-06-23
AmB Dose for Cryptococcal Meningitis
Amphotericin B, Flucytosine - Cryptococcal Meningitis, HIV Infections
Phase 3UnknownShanghai Public Health Clinical Center402020-01-022019-10-29
A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
Toca 511, Toca FC (extended-release formulation of flucytosine) - Bladder Cancer
Phase 1WithdrawnTocagen Inc.2019-12-012020-03-30
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
TG6002, Flucytosine (5-FC, Ancotil) - Colorectal Neoplasm, Digestive System Neoplasm
Phase 1 / Phase 2TerminatedTransgene512018-10-162023-06-23
Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma
ON-01, ONF - Glioblastoma Multiforme, Gliomas, Malignant
Phase 1 / Phase 2CompletedBeijing Neurosurgical Institute382018-08-012024-08-20
Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients
Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®) - Glioblastoma, Brain Cancer
Phase 1 / Phase 2UnknownAssistance Publique - Hôpitaux de Paris782017-10-122017-11-06
A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care
Toca 511, Toca FC - Newly Diagnosed High Grade Glioma (HGG)
Phase 1WithdrawnTocagen Inc.2017-01-012020-03-30
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Toca 511, Toca FC - Colorectal Cancer, Triple Negative Breast Cancer
Phase 1TerminatedTocagen Inc.212016-07-012020-02-07
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
Toca 511, Toca FC, Lomustine - Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 2 / Phase 3TerminatedTocagen Inc.4032015-11-302020-02-07
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium - Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Phase 1CompletedCity of Hope Medical Center162014-10-282026-11-03
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Toca 511, Toca FC - Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 1CompletedTocagen Inc.172014-02-012018-05-21
Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection
Flucytosine and fluconazole, Fluconazole - Cryptococcal Infection Disseminated
Phase 2TerminatedYale University62013-09-012021-09-29
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
APS001F, Flucytosine (5-FC), 10% maltose - Tumors, Neoplasms
Phase 1 / Phase 2SuspendedAnaeropharma Science, Inc.752012-09-012021-05-12

Showing 20 of 34. Sign in to see all of them.

Conditions studied

Meningitis, Cryptococcal (13)  ·  Glioblastoma (10)  ·  Astrocytoma (9)  ·  HIV Infections (9)  ·  Glioma (8)  ·  Brain Neoplasms (7)  ·  Acquired Immunodeficiency Syndrome (6)  ·  Cryptococcosis (6)  ·  Meningitis (6)  ·  Oligodendroglioma (6)  ·  AIDS-Related Opportunistic Infections (5)  ·  Colorectal Neoplasms (5)  ·  Brain Diseases (2)  ·  Gliosarcoma (2)  ·  Urinary Bladder Neoplasms (2)

Sponsors

Tocagen Inc. (8)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  Pfizer (3)  ·  Transgene (3)  ·  City of Hope Medical Center (2)  ·  ANRS, Emerging Infectious Diseases (1)  ·  Anaeropharma Science, Inc. (1)  ·  Ashish Shah (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Beijing Neurosurgical Institute (1)  ·  Duke University (1)  ·  InterMune (1)  ·  Novartis Pharmaceuticals (1)  ·  Peking Union Medical College Hospital (1)  ·  Shanghai Public Health Clinical Center (1)

Countries

United States (19)  ·  France (4)  ·  China (3)  ·  Canada (2)  ·  Belgium (1)  ·  Burma (1)  ·  Burundi (1)  ·  Côte d’Ivoire (1)  ·  Germany (1)  ·  Israel (1)  ·  Kenya (1)  ·  Peru (1)  ·  Puerto Rico (1)  ·  South Africa (1)  ·  South Korea (1)

Top investigators

Asha Das, MD (4)  ·  Jana Portnow (2)  ·  Ana-Claire L Meyer, MD, MSHS (1)  ·  Armstrong D (1)  ·  Ashish Shah, MD (1)  ·  David B Meya (1)  ·  David R Boulware (1)  ·  J Jacobson (1)  ·  Jaime R Merchan, MD (1)  ·  Judith K Kwasa, MBChB MMed (1)  ·  Manish Aghi, MD, NS (1)  ·  Mark A Jacobson, MD (1)

Results publications

PMID 27252174, PMID 28177438, PMID 29322091, PMID 29735994, PMID 29762717, PMID 33119048, PMID 40795226

NIH funding

2015 (1), R21CA282543 (1), R21NS077858 (1)